Covenant Waiver Extension

Summary by AI ^BETAClose X

Litigation Capital Management Limited has secured an extension of its debt covenant waiver from Northleaf Capital Partners (Canada) Ltd until January 31, 2026, with the existing 2.00% per annum interest increase remaining in effect during this period and no additional waiver fee. This extension reflects Northleaf's continued support as LCM's strategic review progresses, with an update expected in the new year.

Disclaimer*

Litigation Capital Management Ltd

30 December 2025

Litigation Capital Management Limited

("LCM" or the "Company")

Covenant Waiver Extension

Litigation Capital Management Limited ("LCM"), an alternative asset manager specialising in dispute financing solutions internationally, announces that the debt covenant waiver from its lender, Northleaf Capital Partners (Canada) Ltd ("Northleaf"), that was due to expire on 30 December 2025 has been extended to 31 January 2026. During the extended waiver period the interest on the loan remains increased by 2.00% per annum consistent with the initial waiver. There is no additional one-time waiver fee in relation to this extension.

The Strategic Review that was first announced on 15 September 2025 has continued to progress and this waiver extension is reflective of Northleaf's ongoing support. LCM management will provide an update on the progress of the Strategic Review in the new year.

Enquiries

Litigation Capital Management
Patrick Moloney, Chief Executive Officer David Collins, Chief Financial Officer

Cavendish (Nomad and Broker)	Tel: 020 7220 0500
Jonny Franklin-Adams and Isaac Hooper (Corporate Finance) Tim Redfern (Corporate Broking)

www.lcmfinance.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END